Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Patients With Relapsed Small Cell Lung Cancer: A Single-Center, Single-Arm, Exploratory Study

NCT07874581 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT07874581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Patients With Relapsed Small Cell Lung Cancer: A Single-Center, Single-Arm, Exploratory Study
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Not applicable
Overall status
Recruiting
Start date
October 1, 2026
Completion date
December 31, 2029
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed small cell lung cancer (sclc)